Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy

Background Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) is a predictor of improved outcomes in breast cancer. In patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative breast cancer, the response to NAC is variable and mostl...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2020-11, Vol.20 (1), p.1-10, Article 1106
Main Authors: Lee, In Hee, Lee, Soo Jung, Lee, Jeeyeon, Jung, Jin Hyang, Park, Ho Yong, Jeong, Shin Young, Lee, Sang-woo, Chae, Yee Soo
Format: Article
Language:English
Subjects:
Adjuvant chemotherapy
Biopsy
Breast cancer
Cancer therapies
Care and treatment
CAT scans
Chemotherapy
Diagnosis
Epidermal growth factor
ErbB-2 protein
Gene amplification
Genetic aspects
Health aspects
Hormone receptors
Lymphatic system
Medical prognosis
Metabolism
Methods
Neoadjuvant chemotherapy
Pathologic complete response
Patient outcomes
Patients
Positron emission tomography
Surgery
SUVmax
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) is a predictor of improved outcomes in breast cancer. In patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative breast cancer, the response to NAC is variable and mostly limited. This study was an investigation of the predictive relevance of parameters of .sup.18F-FDG PET/CT for the pCR to NAC in patients with HR-positive, HER2-negative breast cancer. Methods: AH total of 109 consecutive HR-positive and HER2-negative breast cancer patients who were treated with NAC were enrolled in this prospective cohort study. The relationships between pretreatment .sup.18F-FDG PET/CT and clinical outcomes including pathologic response to NAC were evaluated. Results: All patients finished their planned NAC cycles and eight patients (7.3%) achieved pCR. In the receiver operating characteristic (ROC) curve analysis, pSUVmax exhibited high sensitivity and specificity for predicting pCR. Furthermore, multivariate logistic regression analysis revealed pSUVmax as a predictive factor for pCR (hazard ratio = 17.452; 95% CI = 1.847-164.892; p = 0.013). Conclusion The results of this study suggest that .sup.18F-FDG PET/CT pSUVmax is a predictive factor for pCR of HR-positive, HER2-negative breast cancer to NAC. Keywords: Breast cancer, Neoadjuvant chemotherapy, Pathologic complete response, SUVmax
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-020-07505-w